- This topic is empty.
-
AuthorPosts
-
2026-11-19 at 5:51 pm #10474
Understanding the Need for Transcatheter Heart Valve Preclinical Testing
Transcatheter heart valve technologies represent one of the most anatomically and procedurally demanding categories of cardiovascular devices. Before any such device can move toward clinical application, developers must generate reliable preclinical evidence covering safety, performance, and surgical feasibility. This is precisely the industry pain point that Guangzhou Huateng Biomedical Technology Co., Ltd., operating under the brand HuaTeng Biotech, is positioned to address. As a professional preclinical Contract Research Organization (CRO), the company specializes in animal model development, translational medicine research, and medical device preclinical evaluation—capabilities that are directly relevant to transcatheter heart valve testing programs.

Why Large Animal Models Matter for Transcatheter Heart Valve Evaluation
A core challenge in cardiovascular device development is that smaller rodent models often fail to replicate human anatomy, organ size, and surgical accessibility. Transcatheter heart valve procedures require models with vascular structures and organ dimensions comparable to humans in order to produce clinically meaningful data. HuaTeng Biotech’s Large Animal Model Platform is built to meet this requirement. Among its key features, Porcine/Mini-Pig Models are specifically used for cardiovascular applications including stents and valves, reflecting their anatomical similarity to human cardiovascular systems. In addition, Canine Models support cardiovascular research more broadly, while the platform’s overall differentiated value lies in its anatomical similarity—offering organ sizes and vascular structures comparable to humans—and its capacity for surgical translation, enabling operator training and workflow evaluation for complex surgeries such as valve implantation.

HuaTeng Biotech’s Platform Capabilities for Cardiovascular Device Testing
Supporting these animal models is a broader technology platform infrastructure. The company’s Large Animal Surgery Platform explicitly covers cardiovascular procedures, alongside orthopedic, dental, ophthalmic, and general surgical categories. This is paired with an Imaging and Analytical Platform that includes CT, DSA, OCT, DR, Micro-CT, and ultrasound modalities—imaging technologies that are essential for visualizing valve placement, assessing hemodynamic performance, and monitoring post-implantation outcomes. Notably, the company has stated technical metrics describing capabilities for simultaneous large animal surgeries and complex cardiovascular interventions, which speaks directly to the procedural demands of transcatheter heart valve testing.

Beyond surgical and imaging capacity, HuaTeng Biotech also maintains laboratory platforms spanning cell biology, molecular biology, hematology, and histopathology. These resources allow for integrated data analysis—combining imaging analysis, pathology assessment, and biological evaluation—into a single study report, which is essential for interpreting how a transcatheter valve interacts with surrounding tissue over time.
Regulatory Compliance and Certifications Supporting Global Submissions
For any transcatheter heart valve program, regulatory alignment is non-negotiable. HuaTeng Biotech’s service capabilities are explicitly described as being aligned with international medical device development requirements, including FDA, CE/MDR, and ISO 10993 standards. The company follows FDA GLP principles and OECD GLP standards, and holds AAALAC International Accreditation, CNAS Laboratory Accreditation, and CMA Certified Testing Programs. These certifications, combined with its status as a National High-Tech Enterprise and a Specialized and Innovative Enterprise, provide a compliance framework intended to support regulatory-ready data generation for global submissions, whether a sponsor is pursuing FDA clearance in the United States or CE/MDR certification in the European Union.

Proven Track Record: Case Studies and Market Validation

HuaTeng Biotech’s documented project history includes several cardiovascular-adjacent and device-evaluation cases. Among the FDA-related projects, one involved a fluorescence 3D endoscopic imaging system evaluation conducted in miniature pigs—demonstrating the company’s applied use of porcine models for complex imaging-integrated device assessment. On the CE side, the company has conducted a high-frequency surgical energy platform animal evaluation, illustrating its capacity to support interventional and energy-based device categories relevant to cardiovascular procedures. These cases, drawn from the company’s broader portfolio of FDA-related and CE-related projects, reflect the kind of translational research needed to move cardiovascular and transcatheter-related devices through preclinical evaluation.

In parallel, the company’s Disease Animal Model Platform offers cardiovascular disease models—including myocardial infarction and hypertension models—as part of a library exceeding 200 established animal disease models covering nearly all major human organ systems. This breadth of coverage allows cardiovascular device developers to pair structural device testing with disease-state models when efficacy or pathological response data is required.
Comprehensive Service Scope from Design to Data Interpretation

A transcatheter heart valve preclinical program typically spans multiple stages, and HuaTeng Biotech structures its service scope accordingly: study consultation, experimental design, animal model selection, surgical implementation, device implantation, postoperative monitoring, sample collection, and final data interpretation. This one-stop CRO partnership model is intended to integrate multidisciplinary capabilities from model establishment through to final data interpretation, reducing the need for sponsors to coordinate across multiple vendors. The company’s facilities support this scope at scale, with more than 10,000 m² of laboratory space and total animal production and research facilities exceeding 40,000 m², distributed across its Guangzhou headquarters, Shenzhen Research Center, Hong Kong office, and experimental animal production centers in Guangdong and Jiangsu.

A Platform Built Around Translational Relevance

For developers evaluating a transcatheter heart valve testing CRO, the central considerations are anatomical relevance, surgical translation capability, imaging and data integration, and regulatory alignment. HuaTeng Biotech addresses each of these through its combination of large animal models—particularly porcine and mini-pig models suited to cardiovascular device testing—advanced surgical and imaging platforms capable of complex interventional procedures, and a service structure that follows FDA GLP and OECD GLP standards while supporting FDA, CE/MDR, and ISO 10993 submission pathways. Its documented case history across FDA-related and CE-related cardiovascular and device-evaluation projects, combined with industry certifications from AAALAC, CNAS, and CMA, provides sponsors with a documented basis for evaluating the company’s suitability for transcatheter heart valve and related cardiovascular device preclinical programs. As global medical device manufacturers, pharmaceutical companies, and biotechnology startups continue to seek integrated preclinical partners, HuaTeng Biotech’s customized enterprise solutions—tailored to study design, animal species, and regulatory objectives—position it as a resource worth evaluating within the cardiovascular and transcatheter device testing space.
https://en.htscience.com
Guangzhou Huateng Biomedical Technology Co., Ltd. -
AuthorPosts
- You must be logged in to reply to this topic.
